Fifty-Two-Week Results of Clinical and Imaging Assessments of a Patient with Rheumatoid Arthritis Complicated by Systemic Sclerosis with Interstitial Pneumonia and Type 1 Diabetes despite Multiple Disease-Modifying Antirheumatic Drug Therapy That Was Successfully Treated with Baricitinib: A Novel Case Report
Joint Authors
Fujita, Yuya
Nawata, Masao
Nagayasu, Atsushi
Someya, Kazuki
Saito, Kazuyoshi
Tanaka, Yoshiya
Source
Issue
Vol. 2019, Issue 2019 (31 Dec. 2019), pp.1-5, 5 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2019-07-09
Country of Publication
Egypt
No. of Pages
5
Main Subjects
Abstract EN
Baricitinib is a Janus kinase 1/2 (JAK1/2) inhibitor used in the treatment of rheumatoid arthritis.
A 71-year-old woman with rheumatoid arthritis complicated by systemic sclerosis and type 1 diabetes that were resistant to multiple disease-modifying antirheumatic drugs started treatment with baricitinib.
After baricitinib administration, the disease activity of her rheumatoid arthritis was attenuated from the early stage of treatment, and the effect was maintained for up to 52 weeks.
In addition, the skin sclerosis in systemic sclerosis showed an improvement.
Regarding the influence on type 1 diabetes, the required daily dose of insulin and hemoglobin A1c (HbA1c) levels decreased.
To date, no studies have demonstrated the effectiveness of baricitinib on systemic sclerosis or type 1 diabetes.
We report that baricitinib was effective for systemic sclerosis and type 1 diabetes, as well as for rheumatoid arthritis, for up to 52 weeks.
American Psychological Association (APA)
Fujita, Yuya& Nawata, Masao& Nagayasu, Atsushi& Someya, Kazuki& Saito, Kazuyoshi& Tanaka, Yoshiya. 2019. Fifty-Two-Week Results of Clinical and Imaging Assessments of a Patient with Rheumatoid Arthritis Complicated by Systemic Sclerosis with Interstitial Pneumonia and Type 1 Diabetes despite Multiple Disease-Modifying Antirheumatic Drug Therapy That Was Successfully Treated with Baricitinib: A Novel Case Report. Case Reports in Rheumatology،Vol. 2019, no. 2019, pp.1-5.
https://search.emarefa.net/detail/BIM-1144250
Modern Language Association (MLA)
Fujita, Yuya…[et al.]. Fifty-Two-Week Results of Clinical and Imaging Assessments of a Patient with Rheumatoid Arthritis Complicated by Systemic Sclerosis with Interstitial Pneumonia and Type 1 Diabetes despite Multiple Disease-Modifying Antirheumatic Drug Therapy That Was Successfully Treated with Baricitinib: A Novel Case Report. Case Reports in Rheumatology No. 2019 (2019), pp.1-5.
https://search.emarefa.net/detail/BIM-1144250
American Medical Association (AMA)
Fujita, Yuya& Nawata, Masao& Nagayasu, Atsushi& Someya, Kazuki& Saito, Kazuyoshi& Tanaka, Yoshiya. Fifty-Two-Week Results of Clinical and Imaging Assessments of a Patient with Rheumatoid Arthritis Complicated by Systemic Sclerosis with Interstitial Pneumonia and Type 1 Diabetes despite Multiple Disease-Modifying Antirheumatic Drug Therapy That Was Successfully Treated with Baricitinib: A Novel Case Report. Case Reports in Rheumatology. 2019. Vol. 2019, no. 2019, pp.1-5.
https://search.emarefa.net/detail/BIM-1144250
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1144250